SELLAS Life Sciences (SLS) Operating Income (2010 - 2026)

SELLAS Life Sciences (SLS) has reported Operating Income for 15 consecutive years, with -$9.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Operating Income fell 52.6% year-over-year to -$9.3 million; the TTM figure through Mar 2026 stood at -$31.5 million (down 12.65% YoY), while the FY2025 annual figure was -$28.3 million, up 10.28% from the prior year.
• Operating Income retreated to -$9.3 million in Q1 2026 per SLS's latest filing, from -$8.3 million in the prior quarter.
• Across five years, Operating Income topped out at -$6.1 million in Q1 2025 and bottomed at -$16.7 million in Q1 2022.
• Historically, Operating Income has averaged -$8.8 million across 5 years, with a median of -$8.3 million in 2025.
• Annual changes were most pronounced in 2022 — Operating Income tumbled 645.43% — and 2025, when it surged 37.14%.
• SELLAS Life Sciences' Operating Income stood at -$9.4 million in 2022, then rose by 13.43% to -$8.2 million in 2023, then advanced by 15.4% to -$6.9 million in 2024, then slipped by 19.33% to -$8.3 million in 2025, then declined by 12.08% to -$9.3 million in 2026.
• Business Quant data shows SLS's Operating Income at -$9.3 million in Q1 2026, -$8.3 million in Q4 2025, and -$7.1 million in Q3 2025.